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RNA silencing or interference (RNAi) is a gene regulation mechanism in eukaryotes that controls cell differentiation and
developmental processes via expression of microRNAs. RNAi also serves as an innate antiviral defence response in
plants, nematodes, and insects. This antiviral response is triggered by virus-specific double-stranded RNA molecules
(dsRNAs) that are produced during infection. To overcome antiviral RNAi responses, many plant and insect viruses
encode RNA silencing suppressors (RSSs) that enable them to replicate at higher titers. Recently, several human viruses
were shown to encode RSSs, suggesting that RNAi also serves as an innate defence response in mammals. Here, we
demonstrate that the Ebola virus VP35 protein is a suppressor of RNAi in mammalian cells and that its RSS activity is
functionally equivalent to that of the HIV-1 Tat protein. We show that VP35 can replace HIV-1 Tat and thereby support
the replication of a Tat-minus HIV-1 variant. The VP35 dsRNA-binding domain is required for this RSS activity. Vaccinia
virus E3L protein and influenza A virus NS1 protein are also capable of replacing the HIV-1 Tat RSS function. These
findings support the hypothesis that RNAi is part of the innate antiviral response in mammalian cells. Moreover, the
results indicate that RSSs play a critical role in mammalian virus replication.
Citation: Haasnoot J, de Vries W, Geutjes EJ, Prins M, de Haan P, et al. (2007) The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog 3(6): e86. doi:10.1371/
journal.ppat.0030086
Introduction
An important criterion for productive virus infection is
that the virus evades host antiviral immune responses. In
plants, insects, and nematodes, the basis of these protective
immune responses is formed by the RNA interference (RNAi)
mechanism [1–4]. During virus infection, RNAi against the
virus is activated by the production of virus-speciﬁc double-
stranded RNAs (dsRNAs). These virus-speciﬁc dsRNAs are
processed into small interfering RNAs (siRNAs; a 21-nucleo-
tide dsRNA duplex) by the RNAse III–like endonuclease-
denoted Dicer. Subsequently, one strand of the siRNA duplex,
the guide-strand, is incorporated into the RNA-induced
silencing complex (RISC) to target viral mRNAs bearing
complementary sequences for destruction. To overcome this
antiviral RNAi response, viruses encode RNA silencing
suppressors (RSSs) [5]. For plant viruses, RSSs were ﬁrst
described as pathogenicity factors that contribute to high
virus accumulation and disease. One of the best-characterized
suppressors is the tombusvirus-encoded P19 protein. This
protein, which suppresses RNAi both in plants and mamma-
lian cells, blocks RNAi by binding siRNAs via its dsRNA-
binding domain, thereby sequestering the siRNAs from the
RNAi pathway [6]. Another way to block RNAi is via
inhibition of Dicer activity. For example, the turnip crinkle
virus P83 protein was recently shown to speciﬁcally block the
activity of the Dicer-like 4 protein [7].
Activation of RNAi in mammalian cells, either by trans-
fection of synthetic siRNAs or by endogenous expression of
short hairpin RNAs (shRNAs), is a potent new antiviral tool
[8]. These ﬁndings support the idea that RNAi is part of the
innate immune system in mammals. However, in most cases,
virus-speciﬁc siRNAs could not be detected in virus-infected
mammalian cells [9]. So far, virus-speciﬁc siRNAs have only
been identiﬁed in human cells for human immunodeﬁciency
virus type 1 (HIV-1) and the LINE-1 retrotransposon [10–12].
It has been argued that mammalian cells do not need RNAi-
based antiviral responses because they have acquired the
interferon (IFN) response [13]. However, all other eukaryotes
also evolved innate antiviral defence responses. For instance,
plants have pattern recognition receptors, and virus recog-
nition leads to apoptosis and the systemic acquired resistance
response that is analogous to the IFN response in mammalian
cells [14]. Similar to RNAi, the IFN pathway is triggered by
cytoplasmic viral dsRNAs and acts as a sensitive and potent
antiviral response that is involved in innate and subsequent
adaptive immunity.
If RNAi has an antiviral function in mammals, then the
infecting viruses should encode RSSs as they do in plant and
insect viruses. Recently, several mammalian viruses have
been shown to encode viral factors that exhibit RSS activity
in animal cells. These factors include the inﬂuenza A virus
NS1 (NS1), vaccinia virus E3L (E3L), hepatitis C virus Core,
primate foamy virus type 1 (PFV-1) Tas, and the HIV-1 Tat
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proteins, as well as the adenovirus virus-associated RNAs I
and II (VAI and VAII) [11,15–18]. Like plant virus RSSs,
these suppressors block induced RNAi against reporter gene
constructs. Moreover, NS1 and E3L were able to replace the
RNAi suppression function of the b2 protein encoded by
Flock house virus and to support virus replication in insect
cells [17]. Although most of these viral proteins/RNAs are
essential for virus replication, their mode of action is largely
unknown. We and others have shown that the adenovirus
virus-associated RNAs inhibit RNAi by acting as decoy
substrates for Exportin 5, Dicer, and RISC [16,19]. HIV-1 Tat
is thought to block Dicer activity, whereas NS1 and E3L may
sequester dsRNAs and siRNAs [11,17,20]. Strikingly, all RSS
proteins from mammalian viruses possess IFN or protein
kinase R (PKR) antagonistic properties, suggesting that
RNAi and other innate antiviral responses are interrelated
[21–24].
Although there is consensus about the fact that viral factors
can indeed block RNAi in mammalian cells, there is an
ongoing debate about the signiﬁcance for viral replication
[13]. Because non-viral dsRNA-binding proteins such as the
bacterial RNase-III protein can also act as RSSs in plant cells,
it is important to determine the contribution of RNAi
suppression to virus replication [25]. Here, we show that
Tat-mediated RNAi suppression is required for HIV-1 virus
production. Using defective Tat-minus HIV-1 mutants, we
identiﬁed the Ebola virus (EBOV) VP35 protein as a potent
RNAi suppressor that is functionally equivalent to the HIV-1
Tat RSS function. Furthermore, we show that the E3L and
Figure 1. RNAi Suppression by VP35, NS1, and E3L in Mammalian Cells
HEK293T cells or Vero cells were transfected with an expression plasmid for firefly luciferase (Luc), a vector expressing an shRNA against luciferase
(shLuc), expression constructs for various RSSs (VP35, NS1, E3L), or a control GFP expression plasmid. Luciferase expression was measured at 2–3 d post
transfection.
(A and B) Effect of VP35 (100, 300, and 600 ng) on the expression of the silenced luciferase reporter in HEK293T cells (A) and (B) Vero cells.
(C and D) Effect of NS1, E3L, and GFP (600 ng) on expression of the silenced luciferase reporter in HEK293T cells (C) and in (D) Vero cells.
doi:10.1371/journal.ppat.0030086.g001
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Author Summary
Cells have evolved mechanisms to protect themselves from virus
infection. A well-known antiviral mechanism in mammals is the
interferon (IFN) response of the innate immune system. In plants,
insects, and worms, RNA silencing or RNA interference (RNAi) is a
strong antiviral defence mechanism. It is still debated whether RNAi
is also used as an antiviral mechanism in mammals. Many
mammalian viruses encode essential factors that suppress the
innate antiviral responses of the host. Such innate immunity
suppressor proteins, or IFN antagonists, have recently been reported
to also suppress RNAi in mammalian cells. We now demonstrate that
the Ebola virus VP35 protein, a known IFN antagonist, suppresses
RNAi in human cells. In addition, VP35 restores the production of an
HIV-1 variant with a defective RNAi suppressor Tat protein. These
results indicate that RNAi is part of the innate antiviral defence
response in mammals and that viruses need to counteract this
response in order to replicate. Whereas RNAi and INF act in concert
to prevent the infection of mammalian cells, the invading viruses
encode a protein that counteracts both defence mechanisms.
NS1 proteins can also functionally complement the Tat RSS
function and rescue virus production of the HIV-1 Tat-minus
mutants. These data support the role of RNAi in innate
antiviral responses in mammalian cells and the essential role
of RNAi suppression in HIV-1 replication.
Results
Testing Viral IFN Antagonistic Proteins for RNAi
Suppression Activity
At present, all RSS proteins identiﬁed in mammalian
viruses have IFN/PKR antagonistic properties. Previously, it
was shown that the EBOV IFN antagonist protein VP35 is
capable of restoring the replication of an inﬂuenza A virus
mutant with a large deletion in the NS1 gene [21,26], raising
the possibility that VP35 acts as an RSS in mammalian cells.
To investigate the RNAi suppressor activity of EBOV VP35,
we assayed whether this protein is capable of suppressing
shRNA-mediated silencing of a luciferase reporter. HEK293T
cells were co-transfected with expression vectors for lucifer-
ase and ﬁreﬂy luciferase–speciﬁc shRNA (shLuc) [27], and
with an EBOV VP35 expression plasmid containing the
human EF1a promoter. Co-transfection of luciferase with
shLuc resulted in a strong decrease of luciferase expression
(Figure 1A). Addition of the VP35 expression plasmid
suppressed the shRNA-mediated RNAi in a dose-dependent
manner and restored luciferase expression. To exclude that
the observed effect is caused by the IFN antagonistic
properties of VP35, its RSS activity was also determined in
African green monkey kidney Vero cells that have a defect
(IFN) in the IFN pathway [28]. As in HEK293T (IFNþ) cells,
VP35 expression suppressed RNAi in Vero (IFN) cells and
rescued luciferase expression (Figure 1B).
Next, we compared the RSS activity of VP35 with that of
NS1 and E3L, which were previously demonstrated to have
RSS activity in insect and plant cells [17,20,29]. Because insect
and plant cells lack the IFN pathway, the RSS activity was
determined both in HEK293T (IFNþ) and Vero (IFN) cells.
E3L suppressed RNAi in HEK293T cells, whereas NS1 protein
did not (Figure 1C). However, both E3L and NS1 were able to
suppress RNAi in Vero cells. The control expression plasmid
encoding green ﬂuorescent protein (GFP) did not suppress
RNAi-mediated inhibition of luciferase expression (Figure
1D). These data show that VP35, E3L, and NS1 are able to
suppress shRNA-induced RNAi in mammalian cells. Possibly,
the cell type–dependent RSS activity of NS1 follows from
differences in the expression level of certain cellular RNAi
co-factors.
VP35 dsRNA-Binding Capacity Is Required for RSS Activity
VP35 has a dsRNA-binding motif with high similarity to the
dsRNA-binding domain of the NS1 protein [30]. Mutational
analysis has shown that this VP35 domain is important for
suppression of type I IFN responses [30–32]. Because binding
of dsRNA is one of the strategies to suppress RNA silencing,
we wanted to investigate the importance of this domain in
VP35-mediated RSS activity [33,34]. The VP35 dsRNA-bind-
ing domain has been identiﬁed as 304PRACQKSLRPV314. We
tested two mutants containing a single amino acid substitu-
tion, K309A and R312A, and a double mutant, K309A/R312A.
Furthermore, we tested the C-terminal deletion mutant
R300T, which lacks 40 amino acids. Mutants K309A and
K312A have a defect in dsRNA binding, whereas R300T lacks
the complete dsRNA-binding domain [30,31]. The wild-type
VP35 (VP35wt) and the various mutants were cloned in the
expression vector pcDNA3.1 containing the cytomegalovirus
(CMV) promoter. HEK293T cells were co-transfected with
expression vectors for ﬁreﬂy luciferase, shLuc, the wild-type
Figure 2. VP35 dsRNA-Binding Capacity Is Required for RSS Activity
(A) HEK293T cells were co-transfected with expression vectors for firefly
luciferase (Luc), shLuc, the EBOV VP35wt, or the various mutants (K309A,
R312A, and K309/R12A), or a C-terminal deletion mutant R300T (50 ng).
The renilla expression plasmid pRL-CMV was co-transfected as internal
control. Luciferase expression was measured at 2–3 d post transfection.
From the top down, the panels show the relative expression of firefly
luciferase, renilla luciferase, and the ratio firefly/renilla.
(B) HEK293T cells were co-transfected with expression vectors for firefly
luciferase, renilla luciferase, and either the control shLucR, or the active
shLuc in the presence and absence () of VP35wt expression plasmid.
Luciferase expression was measured at 2–3 d post transfection. Shown is
relative luciferase expression corrected for the internal renilla control
(firefly/renilla).
doi:10.1371/journal.ppat.0030086.g002
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EBOV VP35wt, or the various mutants. In addition, a renilla
luciferase expression plasmid (pRL-CMV) was co-transfected
as internal control. Co-transfection of the ﬁreﬂy luciferase
with shLuc resulted in a strong decrease of luciferase
expression (Figure 2A). Addition of the VP35wt expression
plasmid suppressed shRNA-mediated RNAi and restored
luciferase expression. Interestingly, all mutants, in particular
R312A, K309A/R312A, and R300T, were unable to rescue
luciferase expression (Figure 2A). The internal renilla
luciferase control was not affected by the various VP35
expression plasmids, and the ﬁreﬂy/renilla luciferase ratio
showed a similar trend as the ﬁreﬂy luciferase data. These
results indicate that dsRNA binding is essential for VP35-
mediated RNAi suppression in the luciferase assay.
To ensure that the effect of VP35wt is speciﬁc for the
silenced luciferase, we tested the effect of VP35wt on
luciferase expression in the presence of an inactive shRNA
against luciferase, shLucR. In shLucR, the hairpin cassette has
been inserted in reversed orientation, making it inactive as
RNAi inducer [27] (Figure 2B). Co-transfection of the
luciferase expression plasmid with shLucR did not affect
luciferase expression, whereas shLuc induced a marked
Figure 3. The Tat-Minus HIV-1 Complementation System
(A) Schematic of the HIV-rtTA genome. In HIV-rtTA, the Tat-TAR transcriptional axis has been inactivated by mutation of both the Tat protein and the
TAR hairpin (as indicated), and replaced by the tetracycline-inducible tetO-rtTA system. For this, the rtTA gene was inserted in place of the Nef gene and
eight tetO sites were inserted in the LTR promoter. Upon administration of dox, rtTA can bind to tetO and activate transcription and viral replication. A
frame shift mutation was introduced at codon 20 of the Tat gene.
(B) Virus production in HEK293T cells transfected with HIV-rtTA-Tatwt or HIV-rtTA-Tatfs in the absence () or presence (þ) of dox. CA-p24 in the culture
supernatant was measured at 3 d post transfection.
doi:10.1371/journal.ppat.0030086.g003
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reduction in luciferase expression. Co-transfection of the
VP35wt expression plasmid did not stimulate luciferase
expression in the presence of shLucR, whereas it did enhance
luciferase expression in the presence of shLuc. These results
show that VP35-stimulated reporter expression is speciﬁc for
an RNAi-silenced reporter.
A Second Function of HIV-1 Tat Is Required for Virus
Production
RSS proteins derived from plant or insect viruses, but also
NS1 and E3L, have been identiﬁed by their ability to
functionally complement attenuated viruses that lack their
own RSS [17,35]. Since it has recently been shown that the
HIV-1 Tat protein has RSS activity, we wanted to determine
whether EBOV VP35 is capable of functionally replacing the
Tat RSS activity in HIV-1. To do this, one needs a Tat-minus
virus, but such variants are completely replication impaired
due to a transcription defect. However, we previously
constructed the HIV-rtTA virus, in which Tat-mediated
transcription transactivation is inactivated and replaced by
the Tet-On system (Figure 3A) [36,37]. This virus is fully
dependent on doxycycline (dox) for gene expression and
replication. To test whether the Tat function can be removed
in this context, we introduced a frame shift at Tat codon 20
by a single nucleotide deletion in the Tat open reading frame.
Virus production was measured in HEK293T cells transfected
with the HIV-rtTA molecular clone encoding Tatwt (HIV-
rtTA-Tatwt) or the frame shift mutant Tatfs (HIV-rtTA-Tatfs).
Both constructs produced virus in a dox-dependent manner,
but Tatfs produced much less virus than HIV-rtTA-Tatwt
(Figure 3B). Because HIV-rtTA is not dependent on Tat-
mediated transcriptional activation, this result indicates that
Tat is needed for an additional function.
HIV-1 Tat-Mediated Transactivation of Transcription and
RNAi Suppression
To investigate whether the observed production defect of
HIV-rtTA-Tatfs is caused by inactivation of Tat RSS activity,
we studied rescue of HIV-rtTA-Tatfs by co-transfection of
expression plasmids for Tatwt and two Tat mutants, TatF32A
and TatY26A [38]. We ﬁrst determined the transcriptional
activity of TatF32A and TatY26A. For this, we used TZM-bl cells
that contain the ﬁreﬂy luciferase reporter gene under control
of the HIV-1 long terminal repeat (LTR), which is Tat
responsive. Only transfection of Tatwt expression plasmid
activated luciferase expression, whereas the Tat mutants
TatF32A and TatY26A did not stimulate luciferase expression
(Figure 4A). We next determined the RSS activity of HIV-1
Tatwt, TatF32A, and TatY26A using the luciferase RNAi assay.
Tatwt and TatY26A were capable of suppressing shLuc-
mediated silencing of the luciferase expression, but mutant
TatF32A did not suppress RNAi (Figure 4B). Because both
mutants express stable proteins that lack transactivation
capacity [38], this result indicates that RSS activity can be
separated from transcriptional activity, which is in agreement
with the results described by Bennasser et al. in 2005 [11].
We next determined whether the production defect of
HIV-rtTA-Tatfs in HEK293T cells could be restored by co-
expression of Tatwt, TatF32A, or TatY26A. Tatwt and TatY26A,
which are capable of suppressing shRNA-mediated silencing
of luciferase expression, rescued the production of HIV-
rtTA-Tatfs (Figure 4C). However, TatF32A, which did not
suppress RNAi, could not restore virus production. These
data indicate that the defect in HIV-rtTA-Tatfs virus
production is caused by a trans-acting RSS defect, rather
than a cis-acting defect, of the frame shift mutation.
Complementation of HIV-rtTA-Tatfs by Heterologous RNAi
Suppressor Proteins
We subsequently tested whether the HIV-rtTA-Tatfs pro-
duction defect could also be restored by co-transfection of
the EF1a expression plasmids for VP35, NS1, or E3L. Indeed,
VP35 rescued virus production of HIV-rtTA-Tatfs (Figure
5A). Little RSS activity was measured for E3L and NS1 (Figure
5A), but increasing activity was measured when more RSS
DNA was used in the transfection (Figure 5B). In the latter
case, a GFP reporter was included as a negative control. To
exclude that VP35, E3L, NS1, and Tatwt stimulate HIV-rtTA-
Tatfs virus production by inducing promoter activity, we
Figure 4. Tat-Mediated RNAi Suppression Is Essential for HIV-rtTA Virus
Production
(A) TZM-bl cells containing a Tat-responsive firefly luciferase reporter
gene under control of the HIV-1-LTR were transfected with pBluescript
(), Tatwt, TatF32A, or TatY26A. Luciferase expression was determined 2 d
post transfection.
(B) Transfection of HEK293T cells with the luciferase reporter expression
plasmid (Luc), the vector expressing an shRNA against luciferase (Luc þ
shLuc), and expression plasmids for Tatwt , TatF32A, or TatY26A. Luciferase
expression was determined 2 d post transfection.
(C) Virus production 2 d post transfection in HEK293T cells transfected
with HIV-rtTA-Tatfs and expression plasmids for Tatwt, TatF32A, or TatY26A.
doi:10.1371/journal.ppat.0030086.g004
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transfected cells with a ﬁreﬂy luciferase reporter under
transcriptional control of the 8tetO promoter (the same
promoter as in HIV-rtTA-Tatfs) with an rtTA expression
plasmid and with the different RSS vectors. We measured
dox-dependent promoter activity resulting in luciferase
expression (Figure 5C). Co-expression of Tatwt, E3L, VP35,
NS1, or GFP did not further increase luciferase expression,
indicating that these proteins do no activate the 8tetO
promoter in trans. The various RSS proteins also did not
activate expression of a luciferase reporter under control of a
wild-type HIV-1 LTR promoter in TZM-bl cells (Figure 5D).
This shows that the observed rescue of the Tat function by the
heterologous RSSs is independent of promoter activation.
To conﬁrm that the observed rescue of virus production
corresponds with an increase in viral mRNAs, we analysed
viral RNA accumulation by Northern blot analyses. First,
rescue of HIV-rtTA-Tatfs virus production by Tatwt and VP35
was determined by measuring CA-p24 production in the
supernatant (Figure 6A). The amount of full-length genomic
RNA of HIV-rtTA-Tatfs accumulating in transfected cells was
reduced when compared to that of HIV-rtTA-Tatwt (Figure
6B). In accordance with the CA-p24 values, co-transfection of
Tat and VP35 restored the amount of full-length HIV-1 RNA.
VP35 dsRNA-Binding Capacity Is Required for trans
Complementation of HIV-rtTA-Tatfs
Next, we wanted to determine whether the VP35 dsRNA-
binding capacity is required for the complementation of
HIV-rtTA-Tatfs. HEK293T cells were transfected with either
HIV-rtTA-Tatwt or HIV-rtTA-Tatfs, and expression plasmids
for Tatwt, VP35wt, and the VP35 mutants K309A, R312A,
K309A/R312A, and R300T (Figure 7). Tatwt, VP35wt, and
K309A were able to rescue HIV-rtTA-Tatfs production, and
co-transfection of mutant R312A partially restored HIV-
rtTA-Tatfs virus production. In contrast, mutants K309/
R312A and R300T were unable to rescue virus production.
These results correlate with the ability of the various VP35
mutants to suppress RNAi in the luciferase assay. Thus, the
data conﬁrm the importance of RNAi suppression in HIV-1
production and that the dsRNA-binding capacity of VP35 is
essential for this activity.
Discussion
Although the importance of antiviral RNAi responses in
plants, nematodes, and insects is ﬁrmly established, it is still
under debate whether RNAi has a similar function in
mammalian cells. If RNAi is a protective antiviral response
in mammals, then virus infection should trigger the produc-
tion of virus-speciﬁc siRNAs; inhibition of RNAi should affect
virus replication, and viruses should have evolved factors that
suppress RNAi [13]. To date, there are only three examples of
virus-speciﬁc siRNAs accumulating in infected mammalian
cells. The human retrotransposon LINE-1 was shown to be
inhibited by transposon-speciﬁc siRNAs, which is similar to
what was previously described for transposon silencing in
Figure 5. Functional Complementation of the Tat RSS Function by VP35, NS1, and E3L
(A and B) HEK293T cells were transfected with HIV-rtTA-Tatwt, HIV-rtTA-Tatfs, and expression plasmids for (A) Tatwt, VP35, E3L, and NS1 (50 ng) or (B) E3L,
NS1, and GFP (10, 100, and 500 ng). Virus production was determined 2 d post transfection.
(C) To measure transcriptional transactivation capacity of the various proteins, HEK293T cells were transfected with a firefly luciferase reporter under
control of the 8tetO promoter (similar to the promoter in the HIV-rtTA constructs), renilla expression vector pRL-CMV, an expression plasmid for rtTA to
activate the promoter in the presence of dox, and the indicated amounts of RSSs. Luciferase expression (plotted as firefly/renilla) was determined 2 d
post transfection. , pBluescript (negative control).
(D) Transcriptional transactivation capacity of the various RSS proteins was measured using TZM-bl cells that contain a Tat-responsive firefly luciferase
reporter gene under control of the HIV-1-LTR. The cells transfected with 0.2 lg of Tat or the indicated RSS expression plasmids. Two to three days after
transfection, luciferase expression was measured., pBluescript (negative control).
doi:10.1371/journal.ppat.0030086.g005
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Caenorhabditis elegans [10,12,39]. Furthermore, there is data
suggesting accumulation of virus-speciﬁc siRNAs during HIV-
1 replication [11]. However, virus-speciﬁc siRNA accumula-
tion in mammalian cells appears to be relatively low
compared to that in plant and insect cells. The reason for
this has remained unclear. One explanation could be the lack
of host RNA-dependent RNA polymerase (RdRp) activity in
mammalian cells. In plants and insects, RdRp activity is
responsible for ampliﬁcation of the RNAi signal. In combi-
nation with viral RSS activity, the absence of RdRp activity
could explain the low siRNA levels in mammalian cells in
comparison to those in plant, insect, or nematode cells.
Another possibility is that antiviral RNAi in mammalian cells
is initiated by cellular microRNAs rather than by de novo
production of siRNAs [15]. This has been suggested for the
primate retrovirus PFV-1, where the cellular miR-32 was
found to target PFV-1 sequences. PFV-1 overcomes micro-
RNA-mediated antiviral pressure by the expressing the RSS
Tas protein. In principle, viruses could also escape from
antiviral microRNA pressure by acquisition of one or a few
point mutations within the target sequence [40,41]. It is
therefore likely that there is a more general RNAi response
against PFV infection that necessitates the presence of an
RSS.
Little is known about enhanced virus replication in cells
with a defective RNAi mechanism. However, recently it has
been reported that HIV-1 replication is increased in human
cells in which Dicer and Drosha expression is inhibited [42].
This suggests that RNAi indeed plays a central role in anti-
HIV-1 defence responses in human cells. Another report
describes enhanced accumulation of the mammalian vesicu-
lar stomatitis virus in C. elegans with a defective RNAi
machinery, which conﬁrms that RNAi has an antiviral activity
in nematodes [4]. The other indication for RNAi-mediated
antiviral activity in mammals is the fact that a number of
mammalian viruses encode potent RSSs. However, it is still
unclear to what extent these suppressors contribute to virus
replication, because these factors have multiple functions
that are difﬁcult to separate. Moreover, the relevance of RSS
activity measured in reporter assays has been questioned
because non-speciﬁc binding of siRNAs by overexpression by
dsRNA-binding proteins might also result in RNAi suppres-
sion [13]. Therefore, it is essential to test the importance of
RSS activity in a viral context instead of in reporter assays.
Using the HIV-rtTA virus as a tool to investigate RNAi
suppression, we were able to separate the transactivation
function of HIV-1 Tat from its RSS function. We showed that
Tat-mediated RSS activity is essential for HIV-1 production
without possible side effects of Tat-mediated transcriptional
transactivation. These data are in agreement with data
published by Bennasser et al. in 2005 [11]. The HIV-rtTA
virus was used as a tool to identify EBOV VP35 protein as an
RSS that can complement this Tat function. Both HIV-1 Tat
and EBOV VP35 were found to complement HIV-rtTA-Tatfs
production efﬁciently at low concentrations, indicating
speciﬁc RSS activity. Moreover, RSSs encoded by other
mammalian viruses are also able to complement the Tat
RSS activity. The results presented here support the
importance of RNAi in innate antiviral defence responses
in mammalian cells and the essential function of RSSs in
mammalian virus replication.
Figure 6. Analyses of HIV-rtTA-Tatfs Genomic RNA Accumulation
Complemented with Tat and VP35
(A) HEK293T cells were transfected with HIV-rtTA-Tatwt, HIV-rtTA-Tatfs,
and HIV-rtTA-Tatfs in combination with Tatwt or increasing amounts of
VP35. Two to three days after transfection, virus production was
measured via CA-p24 ELISA, and total RNA was isolated.
(B) Total RNA (10 lg) was run on a denaturing agarose gel, and after
blotting, probed with a Nef-specific radiolabeled probe. Relative
genomic RNA accumulation was quantified by phosphorimaging and is
indicated below. The RNA accumulation of the HIV-rtTA-Tatwt was set at
100%.
doi:10.1371/journal.ppat.0030086.g006
Figure 7. VP35 dsRNA-Binding Capacity Is Required for trans Comple-
mentation of HIV-rtTA-Tatfs
HEK293T cells were transfected with HIV-rtTA-Tatwt, HIV-rtTA-Tatfs, and
expression plasmids for Tatwt, VP35wt, or the various VP35 mutants
(K309A, R312A, and K309/R12A), or a C-terminal deletion mutant R300T
(50 ng). Virus production was determined 2 d post transfection.
doi:10.1371/journal.ppat.0030086.g007
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In plants, insects, and nematodes, antiviral RNAi responses
are triggered by virus-speciﬁc dsRNAs. In mammalian cells,
virus-speciﬁc dsRNAs induce the IFN pathway via members of
the Toll-like receptor family, or via a replication-dependent
pathway involving the cytoplasmic dsRNA sensors RIG-I/
MDA5 (retinoic-acid-inducible protein I/melanoma-differ-
entiation-associated gene 5) [43,44]. Other antiviral proteins
that are induced by dsRNA include the 29-59 oligoadenylate
cyclase (29-59 OAS)/RNAseL and PKR [45,46]. Since RNAi, IFN
responses, and 29-59 OAS/RNAseL/PKR are triggered by
dsRNA, it is likely that these pathways cooperate in the
innate antiviral defence response. The helicases RIG-I/MDA5
are candidate proteins that could link antiviral RNAi and IFN
responses because they can be activated by siRNAs [44,47].
In agreement with this model is the recent observation that
EBOV VP35 inhibits RIG-I induced activation of type I IFN
responses [31]. In part, this inhibition is dependent on
dsRNA-binding capacity of VP35 [31]. The K309A mutant was
shown to have a partial defect in IFN antagonistic activity,
whereas the other mutants, R312A, K309A/R312A, and
R300T, were severely impaired in blocking IFN responses.
Similarly, our assays show that mutation of the dsRNA-
binding domain results in a loss of RNAi suppression activity.
Only mutant K309A showed partial RSS activity and was able
to complement HIV-rtTA-Tatfs production. These data
suggest that VP35-mediated RNAi suppression and VP35-
dsRNA-dependent IFN antagonistic properties are linked. We
therefore propose that VP35 is able to sequester virus-speciﬁc
siRNAs or dsRNA precursors of siRNA, resulting in suppres-
sion of an antiviral RNAi response that acts upstream of the
29-59 OAS/RNAseL/PKR and IFN pathways. In this scenario,
the amount of cytoplasmic virus–speciﬁc siRNAs needs to
reach a certain threshold level before RIG-I/MDA5 and the
IFN pathway are activated (Figure 8). In this way, virus-
speciﬁc siRNAs would function as signal molecules for
activation of the IFN response.
Virus-mediated RNAi suppression therefore has two
functions. First, it suppresses the RNAi response that acts as
the ﬁrst line antiviral defence. Second, the inhibition of
siRNA accumulation prevents RIG-I/MDA5-mediated activa-
tion of the IFN pathway. Important in this respect are the
immature plasmacytoid dendritic cells (PDCs), which play a
predominant role in antiviral immunity. If the accumulation
of virus-speciﬁc siRNAs in these cells is blocked by viral RSS
activity, there will be no trigger to induce the secretion of
class I IFNs that in turn induce a range of antiviral genes,
resulting in the antiviral state of the neighbouring cells,
dendritic cell maturation, and subsequent adaptive immunity
[48]. This results in a delayed onset of the immune responses,
and neighbouring cells will remain permissive to the invading
virus for a prolonged time [49].
Evasion of antiviral immune responses is a key process
during virus replication. The results presented here suggest
that RNAi plays an important role in innate antiviral
defences and that HIV-1 needs to counter this mechanism
in order to replicate. The fact that many RSS proteins also
have IFN antagonistic properties [50–56] supports the idea
that RNAi and IFN responses work together against invading
viruses. It remains to be determined how the RNAi and IFN
responses cooperate in mechanistic terms. In addition, future
experiments should reveal the precise viral signature that
activates the antiviral RNAi response in mammals.
Although viral RSS factors will be able to counter RNAi
during natural infections, these factors will likely not reduce
the effectiveness of RNAi-based antiviral therapeutics. High
concentrations of exogenous synthetic siRNAs, for example,
to block EBOV replication will easily saturate the VP35 RSS
activity, rendering VP35 ineffective, and subsequently still
inhibit virus replication [57]. Similarly, plant viruses that
encode RSS factors can also be silenced by RNAi, as can
viruses such as HIV-1, inﬂuenza, hepatitis C virus, and Flock
house virus that encode RSS factors.
Besides revealing novel aspects of the virus–host inter-
action, the in trans complementation of viruses lacking their
RSS by heterologous RSSs creates opportunities for improv-
ing production of virus particles in mammalian cells. More-
over, this phenomenon could be used to develop a new
generation of live attenuated viral vaccines that improves
upon the current antiviral measures.
Materials and Methods
Construction of expression plasmids. The NS1 (from inﬂuenza A
virus strain PR8 [20]), VP35 (from Ebola virus strain Zaire), E3L (from
vaccinia virus strain Ankara), and EGFP open reading frames were
cloned into the mammalian expression vector pEF5-V5-DEST
containing human EF1a promoter using GATEWAY technology
(Invitrogen, http://www.invitrogen.com). The constructs for VP35wt
and the various VP35 mutants contain the CMV promoter
(pcDNA3.1-VP35wt, K309A, R312A, K309A/R312A, and R300T) and
were a kind gift from S. T. Nichol [30]. The HIV-1 Tat expression
plasmids, pcDNA3-wtTat/pKV-wtTat, and the mutants, pcDNA3-
Y26A and pKV-F32A, were described previously [38]. HIV-rtTA-Tatfs
was created by deletion of A58 in the Tat open reading frame of HIV-
Figure 8. Antiviral RNAi Activity and IFN Responses Function together in
Innate Antiviral Defences
During virus replication, virus-specific dsRNA molecules are generated
that are recognized by Dicer and processed into siRNAs. One strand of
the siRNA, the guide-strand, is loaded into RISC, which targets viral RNAs
for destruction. To escape this antiviral pressure, viruses encode RSS
factors that block the RNAi pathway. When virus-specific dsRNA
molecules and siRNAs accumulate above a certain threshold, and
consequently can no longer be masked by the viral RSS, the
cytoplasmatic dsRNA sensors RIG-I/MDA5, PKR, and 2959 OAS/RNAseL
are activated. This results in the activation of range antiviral responses,
including the production of type I IFNs, general translational inhibition,
and RNA degradation. This model clarifies why RSSs like NS1, VP35, and
E3L have been identified as IFN antagonists.
doi:10.1371/journal.ppat.0030086.g008
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rtTA-TatY26A (variant KYK in [37]), thus creating a frame shift at
codon 20.
Cell culture and transfections. Human embryonic kidney
(HEK293T) cells and African green monkey kidney Vero cells were
grown as a monolayer in DMEM (Gibco BRL, http://www.invitrogen.
com) supplemented with 10% fetal calf serum (FCS) (Hyclone, http://
www.hyclone.com), minimal essential medium with non-essential
amino acids, penicillin (100 U/ml), and streptomycin (100 lg/ml) at
37 8C and 5% CO2. One day before transfection, cells were
trypsinized, resuspended in DMEM, and seeded in 24-well plates at
a density of 1.53 105 cells per well. At the time of transfection, the
cells were 60%–70% conﬂuent. The transfection was performed in
duplicates using Lipofectamine 2000 (Invitrogen) according to the
instructions of the manufacturer. For the luciferase RNAi assay, cells
were transfected with 100 ng of luciferase-expressing plasmid pGL3
(Promega, http://www.promega.com) and 10 ng of expression plasmid
shLuc (pShh1-Ff1), from which an shRNA against luciferase is
expressed under control of the U6 promoter [27]. Cells were lysed
2–3 d post transfection in 150 ll of 1x Passive Lysis Buffer (Promega)
by shaking for 30 min at room temperature. The cell lysate was
centrifuged for 5 min at 1,500 rpm, and luciferase expression was
measured in 10 ll of supernatant with the luciferase reporter assay
system (Promega).
For the complementation studies, 100 ng of HIV-rtTA-Tatfs was
transfected with the indicated amounts of RSS plasmid. The total
amount of DNA was brought to 1 lg using pBluescript (Stratagene,
http://www.stratagene.com). Two to three days after transfection,
virus production was determined by measuring CA-p24 levels by
enzyme-linked immunosorbent assay (ELISA).
For the testing of the effect of Tat and the various RSS proteins on
the 8tetO promoter, we transfected HEK293T cells with 20 ng of
8tetO-luc expression plasmid containing a luciferase reporter under
control of the 8tetO promoter (the same promoter as in HIV-rtTA-
Tatfs), 0.4 ng of rtTA expression plasmid, 0.5 ng of pRL-CMV, and the
different RSS vectors. Two to three days after transfection, luciferase
expression was measured.
Transactivation assay. Transcriptional transactivation capacity of
Tat, Tat mutants, and the various RSS proteins was measured using
TZM-bl cells. These cells were obtained from the NIH AIDS Research
and Reference Reagent Program (also termed JC53-BL cells; catalog
number 8129; https://www.aidsreagent.org). TZM-bl cells are genet-
ically modiﬁed Hela cells that express CD4, CXCR4, and CCR5 and
contain the ﬁreﬂy reporter gene under control of the HIV-1 LTR,
which is Tat responsive. The cells were seeded similarly to the
HEK293T cells and transfected with 0.2 lg of Tat or RSS expression
plasmid, and luciferase expression was measured 2–3 d after
transfection.
Northern blot analyses. HEK293T cells (T25 ﬂask) were transfected
with 6.6 lg of HIV-rtTA-Tatwt, HIV-rtTA-Tatfs, and HIV-rtTA-Tatfs
in combination with 0.132 lg of Tatwt or 0.132/0.66/1.32/6.6 lg of
VP35 expression plasmid. Dox was added to the medium to activate
HIV-rtTA virus production. Two to three days post transfection, virus
production was measured via CA-p24 ELISA, and total RNA was
isolated using the mirVana RNA isolation kit (Ambion, http://www.
ambion). For detection of genomic HIV-1 RNAs, gel electrophoresis
of 10 lg of total RNA was performed on a denaturing formaldehyde,
1% agarose gel. RNA was transferred to a positively charged nylon
membrane (Boehringer, http://www.boehringer-ingelheim.com) via
capillary blotting and crosslinked to the membrane with a UV
crosslinker (Stratagene). A 19-nt LNA-modiﬁed oligonucleotide
complementary to the HIV-1 Nef gene was used as a probe, which
was 59 end labeled using the kinaseMax kit (Ambion) in the presence
of 1 ll of [c-32P]ATP (0.37 MBq/ll; Amersham Biosciences, http://www.
gelifesciences.com) and puriﬁed over a MicroSpin G-25 column
(Amersham Biosciences). Prehybridization and hybridization was
performed in Ultrahyb buffer (Ambion) at 60 8C for 30 min and 18 h,
respectively. The membrane was washed twice for 15 min at 60 8C
with high-stringency buffer (0.2x SSC, 0.2% SDS). Images were
obtained using the Typhoon Trio phosphor imager (Amersham
Biosciences).
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